PRELUDE THERAPEUTICS INC Debt Securities, Available-for-sale, Amortized Cost
PRELUDE THERAPEUTICS INC (PRLD) had Debt Securities, Available-for-sale, Amortized Cost of $207.42 million as of 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-02-15
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $207.42M.
- 2023-09-30: Debt Securities, Available-for-sale, Amortized Cost $230.16M.
- 2023-06-30: Debt Securities, Available-for-sale, Amortized Cost $229.25M.
- 2023-03-31: Debt Securities, Available-for-sale, Amortized Cost $154.45M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2023-12-31 | $207.42M 10-K · filed 2024-02-15 |
| 2023-09-30 | $230.16M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $229.25M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $154.45M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $172.81M 10-K · filed 2024-02-15 |
| 2022-09-30 | $174.38M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $197.89M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $216.87M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $260.12M 10-K · filed 2023-03-15 |
| 2021-09-30 | $259.62M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |